Top Markets
#1 Black Phoenix Black Phoenix +166.47%
#2 Islamic Coin Islamic Coin +158.26%
#3 Glidr Glidr +84.34%
#4 Cryptopia Cryptopia +21.05%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#6 Test Test +17.33%
#7 MarsCoin MarsCoin +12.42%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.89%
#9 DOVU DOVU +9.74%
#10 Palladium Network Palladium Network +9.29%
Coin of the day
Black Phoenix Black Phoenix
Ρυθμίσεις
Γλώσσα
Ελληνικά
Νόμισμα
USD
Θέμα
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Κατάταξη σε μετοχές #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Τιμή μετοχής
$0.0005
Τελευταίος συγχρονισμός: 2026-08-11
Κεφαλαιοποίηση
$10.28K
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
US
Εμπόριο VIA Pharmaceuticals, Inc. (VIAP)

Κατηγορία

Healthcare
Ιστορικό μερισμάτων για VIA Pharmaceuticals, Inc. (VIAP)
Η μετοχή VIA Pharmaceuticals, Inc. (σύμβολο: VIAP) κατέβαλε συνολικά 0 μερίσματα.
Το συνολικό ποσό των μερισμάτων (προσαρμοσμένο για διασπάσεις μετοχών) είναι: 0.00
Απόδοση μερίσματος (TTM): 0
Καταβολές μερισμάτων για VIA Pharmaceuticals, Inc. (VIAP) από 2026 έως 2026
Ετήσιες καταβολές μερισμάτων
Έτος Μέρισμα (προσαρμοσμένο για διασπάσεις μετοχών) Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.
Λίστα όλων των καταβολών μερισμάτων
Έτος Μέρισμα Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.
Καταβολές μερισμάτων για παρόμοιες εταιρείες ή ανταγωνιστές
Εταιρεία Αριθμός καταβολών μερισμάτων Χώρα
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
23.00%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.00%
US